The accessibility of weight-loss drugs like Ozempic and Wegovy is expanding in Canada, with a new service offering home deliveries. This development comes as Health Canada has approved generic versions of these medications, making them more affordable and accessible to Canadians. However, the benefits and risks of these drugs are still under scrutiny, with studies highlighting potential side effects and broader health implications.
The Home Delivery Service
Canadian retail pharmacy Rexall, in partnership with Novo Nordisk Canada, has launched a service called Novo Nordisk Care Rx, which provides home access to Ozempic and Wegovy semaglutide injections and Rybelsus oral tablets. This service is available across all Canadian provinces and territories, except Quebec, and is delivered through Rexall's online pharmacy, Rexall Direct. Patients can receive the treatments at home for no additional cost and can chat with a Rexall pharmacist for personalized support.
Generic Versions and Cost
Health Canada has approved two generic versions of semaglutide, one by Dr. Reddy’s Laboratories in India and the other by Apotex, a Canadian company. The average cost of Ozempic injections can be between $200 and $450 per month, depending on the province, while Wegovy's current list price is $5,066 per patient per year, or roughly $400 per month. Generic medications are expected to be 45 to 90 per cent cheaper than the brand-name versions, making them more affordable for Canadians.
Benefits and Risks
While multiple studies have suggested benefits from semaglutide, including weight loss and potential benefits for diabetes and other health conditions, other studies have also found risks. A 2023 study from the University of British Columbia found that GLP-1 drugs were associated with an increased risk of stomach paralysis, pancreatitis, and bowel obstruction. A 2024 Harvard study found that the drugs were linked to an increased risk of sudden and irreversible vision loss and blindness. Common side effects include belching, bloating, constipation, diarrhea, stomach pain, indigestion, and nausea.
Conclusion
The availability of home deliveries and generic versions of Ozempic and Wegovy in Canada is a significant development, making these medications more accessible and affordable. However, the benefits and risks of these drugs are still under scrutiny, and patients should be aware of potential side effects and broader health implications. As the use of GLP-1 drugs expands, further research and monitoring are necessary to ensure patient safety and effectiveness.
